info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of other and ill-defined sites (controls excluding all cancers)

C3_OTHER_OR_ILLDEFINED_SITES_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C76
Cause of death: ICD-9 195
Cause of death: ICD-8 195
Cancer registry: Topography ICD-O-3 C76
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes 3

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

71

diagram downward connector
C3_OTHER_OR_ILLDEFINED_SITES_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF9

Similar endpoints

List of similar endpoints to Malignant neoplasm of other and ill-defined sites (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 71 17 54
Unadjusted prevalence (%) 0.02 0.01 0.03
Mean age at first event (years) 68.22 68.47 68.14

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: C3_OTHER_OR_ILLDEFINED_SITES_EXALLC – Malignant neoplasm of other and ill-defined sites (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Malignant neoplasm of other and ill-defined sites (controls excluding all cancers)

Endpoint not on priority list, no data to show.